

Enfortumab vedotin EV-301

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



QoL data pending



**Serious and disabling adverse effects**



**Other adjustments**



Enfortumab vedotin EV-301

### FINAL SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Genitourinary Cancers

Therapeutic Indication: Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor

Experimental Arm: Enfortumab vedotin

Control Arm: Investigator-chosen ChT (standard docetaxel, paclitaxel or vinflunine)



